APG-1387 is under clinical development by Ascentage Pharma Group International and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect APG-1387’s likelihood of approval (LoA) and phase transition for Colorectal Cancer took place on 30 Nov 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 30 Nov 2021 increased APG-1387’s Phase Transition Success Rate (PTSR) for Metastatic Pancreatic Cancer, and increased PTSR for Nasopharyngeal Cancer.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their APG-1387 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

APG-1387 overview

APG-1387 is under development for the treatment of advanced solid tumor including nasopharyngeal carcinoma, advanced pancreatic ductal adenocarcinoma, advanced non-small cell lung cancer, colorectal cancer, blood cancer, pancreatic cancer, peritoneal carcinomatosis (peritoneal cancer) and hepatitis B. It was under development for the treatment of head and neck cancer, leukemia and lymphoma. The drug candidate is a new chemical entity administered through intravenous and parenteral route. The drug candidate acts by targeting (IAP) inhibitor of apoptosis protein.

Ascentage Pharma Group International overview

Ascentage Pharma Group International (Ascentage Pharma) is a biotechnology company that discovers and develops targeted small-molecule therapies for the treatment of cancer, hepatitis B and age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The company product pipeline includes HQP8361, APG-2449, APG-2575, APG-1252, APG-115, APG-1387, APG-5918, APG-265, AS1266 and UBX1967/1325. Ascentage Pharma lead candidate HQP8361 is a second-generation c-Met kinase inhibitor for the treatment of c-Met positive cancers, gastric cancer, non-small cell lung cancer and liver cancer. It operates research and development centers and production facilities in Hong Kong, China, and the US. Ascentage Pharma is headquartered in Suzhou, Jiangsu, China.

Quick View APG-1387 LOA Data

Report Segments
  • Innovator
Drug Name
  • APG-1387
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Infectious Disease
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.